The Russian Ministry of Health has approved the use of Ilsira drug (levilimab) for the treatment of rheumatoid arthritis (RA), expanding the current list of the indications of the drug, as BIOCAD company stated.
“According to the data of the phase III of SOLAR clinical trial, subcutaneous administration of Ilsira at a dose of 162 mg once a week in adult patients with active RA demonstrated high efficacy and good safety profile. 71% of patients who were administered the drug achieved a 20% improvement according to the ACR criteria at week 12 of the study, and after 24 weeks of treatment, 52% had low activity of rheumatoid arthritis (DAS28-CRP).
